StockNews.com began coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research note published on Wednesday. The firm issued a sell rating on the biotechnology company’s stock.
Brainstorm Cell Therapeutics Stock Performance
NASDAQ:BCLI opened at $0.60 on Wednesday. Brainstorm Cell Therapeutics has a 52-week low of $0.13 and a 52-week high of $3.46. The firm has a market cap of $29.40 million, a price-to-earnings ratio of -1.36 and a beta of 0.22. The business’s fifty day moving average is $0.37 and its 200 day moving average is $0.34.
Hedge Funds Weigh In On Brainstorm Cell Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC grew its position in Brainstorm Cell Therapeutics by 739.2% during the first quarter. Tower Research Capital LLC TRC now owns 8,862 shares of the biotechnology company’s stock worth $29,000 after buying an additional 7,806 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Brainstorm Cell Therapeutics in the 2nd quarter worth about $33,000. XTX Topco Ltd purchased a new position in shares of Brainstorm Cell Therapeutics in the 1st quarter worth about $40,000. Marshall Wace LLP purchased a new position in shares of Brainstorm Cell Therapeutics in the 3rd quarter worth about $58,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Brainstorm Cell Therapeutics in the 2nd quarter worth about $47,000. 14.33% of the stock is currently owned by hedge funds and other institutional investors.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.
See Also
- Five stocks we like better than Brainstorm Cell Therapeutics
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Best Bear Market Funds: Top 3 Investment Options to Consider
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Is DraftKings A Good Bet Ahead of Q1 Earnings?
- What Are Dividend Contenders? Investing in Dividend Contenders
- Mid-Cap Stocks to Outperform the Market This Cycle
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
